Acute Myeloid Leukemia Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Secondary hematological malignancies in patients with sarcoma: A single ‑center retrospective study
Oncol Lett. 2024 Mar 14;27(5):211. doi: 10.3892/ol.2024.14344. eCollection 2024 May.ABSTRACTThe present retrospective study investigated the clinical features and prognosis of secondary hematological malignancies (SHMs) in patients with sarcoma at Korea Cancer Center Hospital (Seoul, South Korea). Patients who had been diagnosed with SHMs after having received treatment for sarcoma between January 2000 and May 2023 were enrolled. Clinical data were collected from the patients' medical records. Clinical characteristics were analyzed, including SHM incidence, type and prognosis. Of 2,953 patients with sarcoma, 18 (0.6%) were...
Source: Oncology Letters - April 4, 2024 Category: Cancer & Oncology Authors: Yoon Jung Jang Hong Kyu Jeong Chang-Bae Kong Won Seok Song Wan Hyeong Cho Dae Geun Jeon Heyjin Kim Sung Hyun Yang Im Il Na Hyo-Rak Lee Hye Jin Kang Source Type: research

Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era
Int J Hematol. 2024 Apr 5. doi: 10.1007/s12185-024-03752-w. Online ahead of print.ABSTRACTGuidelines recommend rasburicase for high-risk patients to prevent tumor lysis syndrome (TLS). However, little information is available on the incidence and outcome of TLS in AML patients. We analyzed 145 patients with AML who underwent induction therapy before the approval of rasburicase to evaluate the incidence of TLS and the necessity of rasburicase as prophylaxis. Three patients had already developed clinical TLS (CTLS) at diagnosis of AML, and another three developed CTLS after the initiation of chemotherapy. In patients without...
Source: International Journal of Hematology - April 4, 2024 Category: Hematology Authors: Yumiko Toda Masahiro Ashizawa Rui Murahashi Hirotomo Nakashima Takashi Ikeda Shin-Ichiro Kawaguchi Takashi Nagayama Kento Umino Daisuke Minakata Kaoru Morita Chihiro Yamamoto Kaoru Hatano Kazuya Sato Shin-Ichiro Fujiwara Ken Ohmine Yoshinobu Kanda Source Type: research

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia
Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285014. Online ahead of print.ABSTRACTAzacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechanism. Pevonedistat inhibits MCL-1 through activation of NOXA, and pevonedistat/azacitidine has previously shown activity in AML. To assess the tolerability and efficacy of adding pevonedistat to azacitidine/venetoclax in relapsed/refractory AML, we conducted a phase I multicenter openlabe...
Source: Haematologica - April 4, 2024 Category: Hematology Authors: Guru Subramanian Guru Murthy Antoine N Saliba Aniko Szabo Alexandra Harrington Sameem Abedin Karen Carlson Laura Michaelis Lyndsey Runaas Arielle Baim Alex Hinman Sonia Maldonado-Schmidt Annapoorna Venkatachalam Karen S Flatten Kevin L Peterson Paula A Sc Source Type: research

Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia
CONCLUSIONS: Our study shows alterations in several biomarkers in acute leukemia and identifies biomarkers associated with risk of bleeding and DVT.PMID:38574862 | DOI:10.1016/j.jtha.2024.03.020 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - April 4, 2024 Category: Hematology Authors: Yohei Hisada Sierra J Archibald Karan Bansal Yanjun Chen Chen Dai Sindhu Dwarampudi Nora Balas Lindsey Hageman Nigel S Key Smita Bhatia Ravi Bhatia Nigel Mackman Radhika Gangaraju Source Type: research

Chromatin Organization in Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) is a heterogenous group of pre-leukemic myeloid malignancies involving ineffective hematopoiesis, morphological bone marrow abnormalities, and increased risk of transformation to acute myeloid leukemia (AML) [1, 2]. At current, morphological examinations of bone marrow cells and peripheral blood counts serve as the primary diagnostic and surveillance tools for MDS patients. While classically observed cytogenetic abnormalities can be pathognomonic in establishing the clonal nature of the disease, mutational abnormalities only play a supportive role in the diagnosis and management of MDS [3]. (...
Source: Experimental Hematology - April 3, 2024 Category: Hematology Authors: Jane Jialu Xu, Aaron D. Viny Tags: Review Source Type: research

Assessment of CYP-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
J Clin Pharmacol. 2024 Apr 2. doi: 10.1002/jcph.2436. Online ahead of print.ABSTRACTAs a selective and potent inhibitor targeting the isocitrate dehydrogenase-2 (IDH2) mutant protein, enasidenib obtained approval from the US Food and Drug Administration (FDA) in 2017 for adult patients with acute myeloid leukemia (AML) with an IDH2 mutation. In vitro investigations demonstrated that enasidenib affects various drug metabolic enzymes and transporters. This current investigation aimed to assess enasidenib on the pharmacokinetics (PKs) of CYP substrates, including dextromethorphan (CYP2D6 probe drug), flurbiprofen (CYP2C9 prob...
Source: The Journal of Clinical Pharmacology - April 2, 2024 Category: Drugs & Pharmacology Authors: Yiming Cheng Xiaomin Wang Atalanta Ghosh Jie Pu Leonidas N Carayannopoulos Yan Li Source Type: research

A Life-Threatening Complication During the Fourth Pregnancy Due to Acute Promyelocytic Leukemia: A Case Report
Acta Med Indones. 2024 Jan;56(1):76-83.ABSTRACTIncidents of leukemia in pregnancy are infrequent with only one case found from 75,000 to 100,000 pregnancies. The pathophysiological mechanism of leukemia during pregnancy is still unclear. Leukemia which occurs in pregnancy is usually acute and predominantly the myeloid type.A 35-year-old woman in her fourth pregnancy with a gestational age of 38-39 weeks, came to the emergency department (ED) with complaints of contractions since 4.5 hours before admission. The contraction was not accompanied by discharge, mucus, or blood, and fetal movements was still active. She denied co...
Source: Acta medica Indonesiana - April 2, 2024 Category: Internal Medicine Authors: Ismy Azizah Sisnawati Kezia Salay Listiana Nur Fadillah Indi Jazilah Jessica Amelinda Mintarjo Atiyatum Billah Agung Sunarko Putra I Dewa Made Widi Hersana Citra Novita Source Type: research

Sweet syndrome induced by FLT3 inhibitors: case report and literature review
CONCLUSION: Attention should be given to this rare complication when FLT3 inhibitors are used for acute myeloid leukemia therapy, and appropriate treatments need to be administered in a timely manner.PMID:38563968 | DOI:10.1080/16078454.2024.2337230 (Source: Hematology)
Source: Hematology - April 2, 2024 Category: Hematology Authors: Linhui Yang Ran Zhang Hongbing Ma Source Type: research